Skip to content

Released May 9, 2025, before the open

10-Q filed May 9, 2025, 39 days after period end · 0001558370-25-007063

Q1 2025 · 10-Q
Revenue$10.11M+169.8% vs Q1 2024−44.5% vs Q4 2024
Net Income-$3.62MN/M vs Q1 2024N/M vs Q4 2024
EPS Diluted-$0.05N/M vs Q1 2024no prior Q4 2024 on file
Operating Income-$4,145,000N/M
Operating Cash Flow-$5,058,000N/M
Free Cash Flowderived-$5,364,000N/M
Margins · derived
Operating margin-41.0%+88.6 pt vs Q1 2024
Net margin-35.8%+86.8 pt vs Q1 2024

What the release said

The release

Same quarter

MetricQ1 2025Q1 2024Q1 2023Q1 2022
Revenue$10.11M$3.75M$9.59M$16.09M
Net Income-$3.62M-$4.60M-$3.13M-$2.29M
EPS Diluted-$0.05-$0.06-$0.05-$0.05

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR